About
THE AURON TEAM
A CULTURE OF INNOVATION
Auron was founded by a world class team of physicians and scientists with proven expertise in bringing effective differentiation therapies to patients. Their initial successes highlighted the untapped potential of this transformative approach. Expanding on this knowledge, Auron has built a multi-omic computational platform that has enabled a unique understanding of the dysregulated differentiation pathways in cancer cells and has identified novel drug targets applicable across multiple tumor indications.
David Millan, Ph.D.
Chief Scientific Officer
“Every day I’m inspired by the energy and motivation of our team as we pioneer a new approach to transformative medicines. Our vision is to change the treatment paradigm for a wide range of cancer types for which there are no effective treatment options, and ultimately transform the lives of patients and their families.”
Meet the team
Leadership
Leadership
Kate Yen, Ph.D.
Founder & CEO
David Millan, Ph.D.
Chief Scientific Officer
Thomas Graeber, Ph.D.
Chief Data Officer
Christopher D. T. Guiffre J.D., MBA
President & COO
Colleen DeSimone
SVP, Finance
Andrea Armstrong
Chief People Officer
Auron Team
Laura Antipov, Ph.D.
Vice President, Program Management & Operations
Andrea Armstrong
Chief People Officer
Jake Axford
Principal Scientist
Maulasri Bhatta, Ph.D.
Senior Scientist, II
Mark Bittinger, PhD..
Vice President, Translational Biology
Tori Brown
Executive Assistant & Operations Manager
Betty Chan, Ph.D.
Director, Biochemistry & Biophysics
Joe DeBartolo, Ph.D.
Senior Director, Data Science
Colleen DeSimone
SVP, Finance
Christopher D. T. Guiffre J.D., MBA
President & COO
Thomas Graeber, Ph.D.
Chief Data Officer
Christina Lee
Senior Scientist, I
David Millan, Ph.D.
Chief Scientific Officer
James Neef
Director, Medicinal Chemistry
Sambad Sharma, Ph.D.
Senior Scientist, II
Roman Shimanovich Ph.D.
Senior Director, CMC
Sara Sinicropi-Yao, Ph.D.
Principal Scientist, Translational Biology
Kimberly Straley
Director, Translational Biology
Henry Wilson, Ph.D.
Principal Scientist, Computational Biology
Kate Yen, Ph.D.
Founder & CEO
Founders
Ross Levine, M.D.
Memorial Sloan Kettering Cancer Center
Eytan Stein, M.D.
Memorial Sloan Kettering Cancer Center
Matthew Vander Heiden, M.D., Ph.D.
Massachusetts Institute of Technology
Kate Yen, Ph.D.
Founder & CEO
Board of Directors
Alexandra Cantley, Ph.D.
Polaris Partners
Anna French, Ph.D.
Qiming Venture Partners USA
Alon Lazarus, Ph.D.
Arkin Bio Ventures
Briggs Morrison, M.D.
Independent Chairman of the Board
Victoria Richon Ph.D.
Independent Board Member
Eric Shiozaki, Ph.D.
DCVC Bio
Kate Yen, Ph.D.
Founder & CEO
Scientific Advisory Board
Stéphane de Botton, M.D., Ph.D.
Gustave Roussy Cancer Center
Richard Chesworth, Ph.D.
Former CSO, Kymera Therapeutics
Ross Levine, M.D.
Memorial Sloan Kettering Cancer Center
Shin-San Michael Su, Ph.D.
Former CSO, Volastra Therapeutics, Inc.
Mikhail (Misha) Roshal, M.D., Ph.D.
Memorial Sloan Kettering Cancer Center
Charles Rudin, M.D., Ph.D.
Memorial Sloan Kettering Cancer Center
Kimberly Stegmaier, M.D.
Harvard Medical School and Dana-Farber Cancer Institute
Eytan Stein, M.D.
Memorial Sloan Kettering Cancer Center
George Thomas, M.D.
Oregon Health & Science University
Matthew Vander Heiden, M.D., Ph.D.
Massachusetts Institute of Technology
Paresh Vyas, MRCP FRCP FRCPath
Oxford University
Investors
These are some of the companies who support our mission:
